Biocon signs deal with Bentley Pharma

Biocon has signed a product licencing agreement with Bentley Pharmaceuticals Inc, a technology-based specialty pharmaceutical and drug delivery company, for Bentley's intra-nasal spray formulation
for administering insulin.

According to a release issued by Biocon to the BSE today, the agreement covers 85 countries, and grants the company exclusive as well as co-exclusive rights to develop and market the product throughout Asia, Africa and the Middle East.

"The company has also entered into a long-term supply agreement which will provide Bentley and its licensees with competitive supply of insulin for worldwide markets," the release added.

Kiran Mazumdar-Shaw, CMD of Biocon, said: "Biocon believes that non-injectable insulins will drive the future of diabetes therapy. Along with our own programme in oral delivery of insulin, this agreement will give us the breadth of opportunity to straddle the entire domain of non-injectable insulin delivery. As one of the largest producers of insulin, this co-operation is of great strategic importance to us."